Previous 10 | Next 10 |
2023-06-13 16:55:45 ET Summary Pfizer presents a buying opportunity as value has deepened following weak price action due to post-pandemic revenue concerns. Aggressive yet speculative acquisitions demonstrate a commitment to pipeline diversification in an effort to grow into ...
2023-06-06 14:44:35 ET Summary Biohaven Ltd is a spinout of assets from Biohaven Pharmaceutical - just before the parent company was acquired by Pfizer last year for >$11bn. Much of the management team that developed Biohaven Pharmaceuticals' Nurtec migraine therapy, plus six o...
2023-06-02 09:11:34 ET Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence . The big gain was sparked by the company's research and d...
2023-06-01 13:42:26 ET Shares of Biohaven Ltd. ( NYSE: BHVN ) added ~14% to reach an all-time high on Thursday following three straight sessions of gains, a day after the neuro-pharmaceutical drug developer conducted its R&D Day. The New Haven, Connecticut-based biotech ...
2023-06-01 10:07:16 ET Gainers: Nanobiotix ( NBTX ) +17% . Veeva Systems ( VEEV ) +13% . Biohaven ( BHVN ) +12% . Rockwell Medical ( RMTI ) +11% . Quipt Home Medical ( QIPT ) +9% . Losers: Lexicon Pharmaceuticals ( LXRX ...
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day PR Newswire Submitted a new drug application (NDA) ...
Biohaven to Present R&D Day at Yale School of Management Biohaven to Present R&D Day at Yale School of Management PR Newswire NEW HAVEN, Conn. , May 25, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceu...
2023-05-12 17:19:52 ET Biohaven press release ( NYSE: BHVN ): Q1 Non-GAAP EPS of -$0.98. Cash, cash equivalents and marketable securities as of March 31, 2023 was $392.0 million. For further details see: Biohaven Non-GAAP EPS of -$0.98
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments PR Newswire Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding C...
Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy PR Newswire NEW HAVEN, Conn. , April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a glo...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...